Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - Applied DNA Sciences reported a quarterly loss of $5.31 per share, which was worse than the Zacks Consensus Estimate of a loss of $4.60, and compared to a loss of $4 per share a year ago [1] - The company posted revenues of $0.93 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 3.33%, but down from $4.41 million in the same quarter last year [1] - Over the last four quarters, Applied DNA Sciences has surpassed consensus EPS estimates two times and revenue estimates two times [1] Stock Performance - Shares of Applied DNA Sciences have declined approximately 69.7% since the beginning of the year, contrasting with the S&P 500's gain of 9.3% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$3.40 on revenues of $0.95 million, and for the current fiscal year, it is -$12.60 on revenues of $3.94 million [4] - The trend of estimate revisions for Applied DNA Sciences is mixed, and future changes in estimates will be closely monitored following the recent earnings report [4] Industry Context - The Security and Safety Services industry, to which Applied DNA Sciences belongs, is currently ranked in the top 12% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [5] - Intellicheck Mobilisa, Inc., another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +42.9% [5][6]